Galectin Therapeutics Inc.(GALT)Earnings, Financials & Key Ratios

Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and clarifies regulatory endpoints. The FDA's endorsement of a single, well-controlled Phase 3 trial with a composite clinical outcome endpoint reduces uncertainty and shortens timelines. GALT's valuation reflects skepticism about execution, financing risk, and commercial viability, but successful Phase 3 results could trigger a significant re-rating.

Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.

NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.